TABLE 1.
Expression levels of the CgCDR1 and CgCDR2 genes and azole susceptibilities for the C. glabrata isolates studied
| Isolate source (time of collection) or control straina | Gene expressionb
|
MIC (μg/ml)
|
||||
|---|---|---|---|---|---|---|
| CgCDR1 | CgCDR2 | Fluconazole | Ketoconazole | Itraconazole | Voriconazole | |
| Blood (T0) | 0.54 | 1.21 | 4 | 0.25 | 0.25 | 0.125 |
| Vagina (T0) | 0.67 | 1.34 | 4 | 0.125 | 0.125 | 0.125 |
| Blood (T1) | 473.32 | 75.21 | 256 | >16 | 4 | 8 |
| Vagina (T1) | 471.23 | 76.98 | 256 | >16 | 8 | 8 |
| ATCC 36909 | 0.69 | 1.05 | 2 | 0.125 | 0.125 | 0.06 |
a
Times of collection are defined in the text. Reference strain C. glabrata ATCC 36909 was used as a control.
b
Quantification was performed by real-time reverse transcription-PCR. Values are averages of four independent experiments and represent increases in gene expression relative to azole-susceptible C. glabrata strain DSY562 (which was arbitrarily set at a value 1.00) (13).